Fairvalue-Calculator Fairvalue-Calculator
EN DE

Perspective Therapeutics, Inc (CATX) Fair Value & Analysis

Healthcare · US · Market cap $336M

Price$3.00
Fair Value$0.7800
Upside-74.0%
Quality95/100
Evidence: Low Range $0.5100 – $0.9700

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Perspective Therapeutics, Inc (CATX) currently trades at $3.00, while our model-based Fair Value estimate is $0.7800 — implying the stock looks roughly 74.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial coll…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Perspective Therapeutics, Inc (CATX) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.7800 versus a price of $3.00 — about −74% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CATX?
Our 21-model fair value for Perspective Therapeutics, Inc is $0.7800 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.00.
What is the quality score of CATX?
Perspective Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.